Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 15/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 2/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5584105 | 1.00 | ADRB2 (0.41) | ADRB2ADRB1CYP3A4ADRB3CYP1A2 | |
| SCHEMBL3619519 | 1.00 | ADRB2 (0.41) | ADRB2ADRB1CYP3A4ADRB3CYP1A2 | |
| SCHEMBL3717727 | 0.88 | ADRB2 (0.38) | ADRB2ADRB1 | |
| SCHEMBL3717721 | 0.88 | ADRB2 (0.38) | ADRB2ADRB1 | |
| SCHEMBL5580934 | 0.88 | ADRB2 (0.38) | ADRB2ADRB1 | |
| SCHEMBL3627697 | 0.87 | ADRB2 (0.53) | ADRB2ADRB1CYP3A4ADRB3CYP1A2 | |
| SCHEMBL3626078 | 0.87 | ADRB2 (0.53) | ADRB2ADRB1CYP3A4ADRB3CYP1A2 | |
| SCHEMBL6046381 | 0.87 | ADRB2 (0.53) | ADRB2ADRB1CYP3A4ADRB3CYP1A2 | |
| SCHEMBL3627693 | 0.87 | ADRB2 (0.53) | ADRB2ADRB1CYP3A4ADRB3CYP1A2 | |
| SCHEMBL3626067 | 0.87 | ADRB2 (0.53) | ADRB2ADRB1CYP3A4ADRB3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730103-B1 | FORMAMIDE DERIVATIVES USEFUL AS ADRENOCEPTOR | PFIZER LTD (GB) | 2010-05-26 | — | — | EP | disclosed |
| US-7547731-B2 | Formamide derivatives for the treatment of diseases | PFIZER INC (US) | 2009-06-16 | — | — | US | disclosed |
| US-20080207689-A1 | Formamide Derivatives For The Treatment of Diseases | PFIZER INC | 2008-08-28 | — | — | US | disclosed |
| US-7241810-B2 | Formamide derivatives for the treatment of diseases | PFIZER INC (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241810-B2 | Formamide derivatives for the treatment of diseases | PFIZER INC (US) | 2007-07-10 | — | — | US | disclosed |
| US-20050215590-A1 | Formamide derivatives for the treatment of diseases | PFIZER LIMITED (GB) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207689-A1 | Formamide Derivatives For The Treatment of Diseases | FH, FAH, HRH4 | ADRB2 751/4885ADRB1 919/4885CYP3A4 183/4885 |
| US-20050215590-A1 | Formamide derivatives for the treatment of diseases | FH, FAH, HRH4 | ADRB2 751/4885ADRB1 919/4885CYP3A4 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.